FDA Considers Safety Exceptions to Salt Drug Labeling Policy

Drug Industry Daily
Sponsors of drugs with salt-based active ingredients are urged to follow the United States Pharmacopeia’s (USP) strict naming rules for such drugs, but the FDA may make an exception when the name of the salt contains “vital information” for clinical use, new draft guidance states.

To View This Article:


Subscribe To Drug Industry Daily